Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Ozempic Knockoffs Survive Crackdown Thanks to Loophole Providers of compounded obesity drugs are finding-for now-a new way into the booming market by tweaking formulations. International Paper Is ...

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO ... losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly (LLY.N), opens new tab.

Headaches are a common and frustrating side effect some people experience while taking the popular weight loss drug Ozempic, but the medication itself may not be to blame. According to fitness and ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

Ozempic maker Novo Nordisk NOVO.B-1.81%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...